AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cytek Biosciences, Inc. Director's Dealing 2021

Jul 27, 2021

32966_dirs_2021-07-26_4300b54b-9a59-4cae-bcbd-3e6448a58678.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytek Biosciences, Inc. (CTKB)
CIK: 0001831915
Period of Report: 2021-07-22

Reporting Person: Jiang Wenbin (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Stock Option (Right to Buy)	$17.00	A	250000	Acquired	2031-07-22	Common Stock (250000)	Direct

Footnotes

F1: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.